2-chloro-n(6)cyclopentyladenosine has been researched along with 6-ketoprostaglandin f1 alpha in 1 studies
| Studies (2-chloro-n(6)cyclopentyladenosine) | Trials (2-chloro-n(6)cyclopentyladenosine) | Recent Studies (post-2010) (2-chloro-n(6)cyclopentyladenosine) | Studies (6-ketoprostaglandin f1 alpha) | Trials (6-ketoprostaglandin f1 alpha) | Recent Studies (post-2010) (6-ketoprostaglandin f1 alpha) |
|---|---|---|---|---|---|
| 252 | 0 | 43 | 4,832 | 294 | 150 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borchard, U; Felsch, A; Stöcker, K | 1 |
1 other study(ies) available for 2-chloro-n(6)cyclopentyladenosine and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Adenosine A1 and A2 receptor agonists alter cardiac functions and prostacyclin release in the isolated guinea-pig heart.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Cells, Cultured; Coronary Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Epoprostenol; Guinea Pigs; Heart; Heart Rate; Male; Myocardium; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Triazoles; Vasodilation; Ventricular Function, Left; Xanthines | 1994 |